Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome

Summary

The PRECISION is a proof-of-concept, phase II randomized clinical trial aiming to evaluate the efficacy and safety of anakinra in patients with Post-Acute COVID Syndrome (PACS) of the pro-inflammatory respiratory phenotype. Improvement is measured by a composite endpoint, namely, the "Score of PACS progression reversal"

Timeline

Start

2023-09-06

Primary completion

2028-03

Completion

2028-03

Drugs

Indications